We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01175109
Recruitment Status : Unknown
Verified December 2012 by Deric M Park MD, University of Virginia.
Recruitment status was:  Active, not recruiting
First Posted : August 4, 2010
Last Update Posted : December 27, 2012
Information provided by (Responsible Party):
Deric M Park MD, University of Virginia

Brief Summary:
This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.

Condition or disease Intervention/treatment Phase
Chordoma Drug: Imatinib + LBH589 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Study Start Date : October 2011
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Chordoma

Arm Intervention/treatment
Experimental: Escalating doses of imatinib and LBH589
Study will incorporate a "3+3" dose escalation design.
Drug: Imatinib + LBH589
Escalating doses of imatinib and LBH589 will be administered.

Primary Outcome Measures :
  1. Number of dose limiting toxicities [ Time Frame: At time of study drug discontinuation ]

Secondary Outcome Measures :
  1. Tumor response [ Time Frame: Week 7 ]
    Tumor response will be evaluated using the RECIST criteria

  2. Tumor response [ Time Frame: Week 12 ]
    Tumor response will be evaluated using the RECIST criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients greater than or equal to 18 years of age.
  • Histologically documented diagnosis of chordoma
  • At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors, see Appendix 3).
  • Performance status 0,1, or 2 (ECOG) (see Section 6)
  • Patients must have adequate bone marrow and end organ function, as defined as the following:

    1. WBC > 3.0 x 109/L
    2. ANC > 1.5 x 109/L,
    3. Platelets > 100 x 109/L
    4. Hemoglobin > 10 gm/dl
    5. Total bilirubin < 1.5 x ULN (Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's disease) grade <3.
    6. AST/SGOT and ALT/SGPT < 2.5 x UNL
    7. Serum creatinine ≤ 2.5 x ULN or 24 hr creatinine clearance ≥ 50ml/min
    8. Serum albumin ≤ 3g/dL
    9. Serum amylase and lipase ≤ 1.5 x ULN
    10. Alkaline phosphatase ≤ 2.5 x ULN
    11. Patients must have the following laboratory values (WNL = within normal limits at the local institution lab) or corrected to within normal limits with supplements prior to the first dose of study medication:

      1. Potassium (WNL)
      2. Magnesium (WNL)
      3. Phosphorus (WNL)
      4. Calcium (WNL)
  • Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • A scan should be performed within 14 days prior to registration. The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement.
  • Patients must have an interval of greater than or equal to 3 months from the completion of radiation therapy to study entry.
  • Patients must be willing to participate in the pharmacokinetic studies.
  • Written, voluntary informed consent.

Exclusion Criteria:

  • Patient has received any other investigational agents within 28 days of first day of study drug dosing for treatment of chordoma, unless the disease is rapidly progressing. Patients who have been previously treated with imatinib or LBH589 are ineligible.
  • Patients must not be on enzyme inducing anticonvulsants or valproic acid, a seizure medication with HDAC inhibition activity.
  • Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
  • Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
  • Impaired cardiac function including any one of the following:

    1. Inability to monitor the QT/QTc interval on ECG
    2. Long QT syndrome or a known family history of long QT syndrome.
    3. Clinically significant resting brachycardia (<50 beats per minute)
    4. QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
    5. Myocardial infarction within 12 months prior to starting study
    6. Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)
    7. History of or presence of clinically significant ventricular or atrial tachyarrhythmias
  • Female patients who are pregnant or breast-feeding.
  • Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  • Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  • Patient has known brain metastasis
  • Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)prior to study entry, unless the disease is rapidly progressing.
  • Patient receiving concurrent treatment with warfarin.
  • Patient previously received radiotherapy to > 25 % of the bone marrow
  • Patient had a major surgery within 2 weeks prior to study entry.
  • Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
  • Patients may not be receiving any other investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to imatinib or LBH589 used in study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01175109

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Deric M Park MD
Layout table for investigator information
Principal Investigator: Deric M Park, MD University of Virginia
Layout table for additonal information
Responsible Party: Deric M Park MD, Assistant Professor, Department of Neurological Surgery, University of Virginia
ClinicalTrials.gov Identifier: NCT01175109    
Other Study ID Numbers: 15120
First Posted: August 4, 2010    Key Record Dates
Last Update Posted: December 27, 2012
Last Verified: December 2012
Keywords provided by Deric M Park MD, University of Virginia:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Histone Deacetylase Inhibitors